‘Building The Plane While Flying It’: Cell And Gene Therapy Makers Prepare For MFN Pricing, Tariffs

 
• By Mandy Jackson
  
Physician-administered and Medicaid-covered drugs, like cell and gene therapies, are most exposed to MFN policy (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

More from Drug Pricing